Robshaw & Julian Associates Inc. Has $3.08 Million Position in Pfizer, Inc. (NYSE:PFE)

Robshaw & Julian Associates Inc. cut its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,528 shares of the biopharmaceutical company’s stock after selling 375 shares during the period. Pfizer comprises approximately 2.2% of Robshaw & Julian Associates Inc.’s holdings, making the stock its 24th largest position. Robshaw & Julian Associates Inc.’s holdings in Pfizer were worth $3,077,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of PFE. Asset Planning Services Ltd. increased its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. increased its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC increased its stake in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. increased its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC increased its stake in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares in the last quarter. Institutional investors own 69.98% of the company’s stock.

Pfizer, Inc. (NYSE PFE) opened at 33.15 on Friday. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $37.39. The firm has a market capitalization of $197.83 billion, a price-to-earnings ratio of 27.90 and a beta of 1.01. The stock’s 50 day moving average price is $33.36 and its 200 day moving average price is $33.24.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. During the same period last year, the company earned $0.67 earnings per share. The firm’s revenue was down 1.7% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer, Inc. will post $2.55 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.86%. Pfizer’s dividend payout ratio (DPR) is 108.48%.

Several brokerages have recently commented on PFE. Jefferies Group LLC restated a “hold” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 10th. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub cut Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Finally, Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the company from $38.00 to $36.00 in a report on Thursday, July 20th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $37.68.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).